Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
Several short-lived, high-energy beta emitters are being proposed as the radionuclide components for molecular- targeted potential cancer therapeutic agents. The laboratory mice used to determine the efficacy of these new agents have organs that are relatively small compared to the ranges of these high-energy particles. The dosimetry model developed by Hui et al. was extended to provide realistic beta-dose estimates for organs in mice that received therapeutic radiopharmaceuticals containing (90)Y, (188)Re, (166)Ho, (149)Pm, (64)Cu, and (177)Lu. Major organs in this model included the liver, spleen, kidneys, lungs, heart, stomach, small and large bowel, thyroid, pancreas, bone, marrow, carcass, and a 0.025-g tumor. The study as reported in this paper verifies their results for (90)Y and extends them by using their organ geometry factors combined with newly calculated organ self-absorbed fractions from PEREGRINE and MCNP. PEREGRINE and MCNP agree to within 8% for the worst-case organ with average differences (averaged over all organs) decreasing from 5% for (90)Y to 1% for (177)Lu. When used with typical biodistribution data, the three different models predict doses that are in agreement to within 5% for the worst-case organ. The beta-absorbed fractions and cross-organ-deposited energy provided in this paper can be used by researchers to predict mouse-organ doses and should contribute to an improved understanding of the relationship between dose and radiation toxicity in mouse models where use of these isotopes is favorable.
Miller
William H
WH
Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO 65211, USA. MillerW@missouri.edu
Hartmann-Siantar
Christine
C
Fisher
Darrell
D
Descalle
Marie-Anne
MA
Daly
Tom
T
Lehmann
Joerg
J
Lewis
Michael R
MR
Hoffman
Timothy
T
Smith
Jeff
J
Situ
Peter D
PD
Volkert
Wynn A
WA
D000818:Animals; D003301:Copper Radioisotopes / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006695:Holmium / Q000627:therapeutic use*; D008187:Lutetium / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D015233:Models, Statistical; D008962:Models, Theoretical; D011399:Promethium / Q000627:therapeutic use*; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000627:therapeutic use*; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012211:Rhenium / Q000627:therapeutic use*; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D003301:Copper Radioisotopes; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; D008187:Lutetium; D012211:Rhenium; D006695:Holmium; D011399:Promethium